Drug data last refreshed 19h ago · AI intelligence enriched 6d ago
CARDIZEM LA is an extended-release oral tablet formulation of diltiazem hydrochloride, a calcium channel blocker used to treat hypertension and angina pectoris. It works by inhibiting calcium influx into vascular smooth muscle and cardiac cells, reducing blood pressure and myocardial oxygen demand. This formulation provides once-daily dosing for improved patient compliance in cardiovascular disease management.
Product is in late-stage lifecycle with modest Part D spending and volume, indicating a mature asset with potential headcount reductions as patent exclusivity erodes.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
CARDIZEM LA roles are limited in number and scope, reflecting the product's mature lifecycle and modest commercial footprint. Professionals joining this team should expect focus on operational efficiency, managed decline, and potential consolidation rather than growth initiatives.
Worked on CARDIZEM LA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo